Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term SPP100 in Essential Hypertension
NCT00246584Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aliskiren in essential hypertension, sponsored by Novartis. Primary endpoint: Incidence of adverse events, vital signs, abnormal laboratory changes at 52 weeks. Started Oct 2004; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00246584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00246584.